Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 21, 2021updated 07 Jan 2022 8:50am

Vesper Medical completes enrolment in venous stent system trial

The VIVID clinical trial will assess the safety and efficacy of the device to treat patients with iliofemoral occlusive disease.

Vesper Medical has completed subject enrolment in the pivotal VIVID clinical trial of the Vesper Duo Venous Stent System.

Designed to be a next generation venous technology, the stent system is developed to advance the deep venous disease treatment for patients with chronic venous insufficiency (CVI).

It comprises a portfolio of self-expanding venous stents, DUO-HYBRID and DUO-EXTEND, which are designed to improve luminal diameter in symptomatic venous outflow obstructions.

Providing clinical versatility, the new device allows physicians to customise the therapy for patients depending on their specific disease location in iliofemoral vein.

The multi-centre, prospective, single-arm, global study has enrolled 160 participants at centres in Europe and the US.

It will assess the Vesper DUO Stent System’s safety and efficacy to treat patients suffering with iliofemoral occlusive disease.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Vesper Medical president and CEO Bruce Shook said: “The rapid enrolment of the VIVID Trial is a testimonial to the magnitude and severity of chronic venous insufficiency and the dedication of our investigators and employees.

“We are thrilled to take this important step toward bringing the novel DUO-HYBRID and DUO-EXTEND venous stent technology to patients suffering with CVI.”

According to the company, up to 35% of the adult population in Europe and the US are affected by CVI.

The company stated that the VIVID Trial will evaluate Vesper DUO venous stent system’s freedom from major adverse events (MAEs) at 30 days post procedure and the stented segment’s primary efficacy will be assessed at 12 months.

Furthermore, the participants enrolled in the study will be followed for three years.

In September this year, Neurolief enrolled first participant in the clinical study of its brain neuromodulation system to treat major depressive disorder (MDD).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU